Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Dr. R.W. Mills, Chief Medical Officer for Nationwide Children's Hospital - Toledo, talks about what to know about RSV as kids ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through ...

The rate of atrial fibrillation was also higher in RSV patients, although it depended on preexisting heart conditions and ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Wealthy Chinese consumers are likely to spend three times more than their peers on post-retirement healthcare over the next ...

Crowded classrooms and sharing supplies make it easy for viruses like the flu, RSV, and the common cold to spread.

Modern medicine is largely reactive—treating illness only after symptoms emerge. But a new study from the Research Institute ...

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...